

























































published: 17 November 2014
doi: 10.3389/fimmu.2014.00589
Arginase in the vascular endothelium: friend or foe?
Rudolf Lucas1,2*, David Fulton1,2, RobertWilliam Caldwell 2 and Maritza J. Romero1,2
1 Vascular Biology Center, Medical College of Georgia, Georgia Regents University, Augusta, GA, USA
2 Department of Pharmacology andToxicology, Medical College of Georgia, Georgia Regents University, Augusta, GA, USA
*Correspondence: rlucas@gru.edu
Edited and reviewed by:
Charles Dinarello, University of Colorado Health Sciences Center, USA
Keywords: arginase inhibitors, eNOS, reactive oxygen species, microvascular permeability, impaired vasorelaxation, vessel wall remodeling, l-citrulline
This special issue, entitled “the role of arginase in endothelial dys-
function,” assembles original contributions (1–4), as well as timely
reviews (5–12) broadly related to the deleterious activities of the
manganese-containing enzyme arginase in the vascular endothe-
lium. The arginase 1 isoform is cytosolic and is mainly localized
in the liver, where it performs a crucial role in eliminating nitro-
gen formed during amino acid and nucleotide metabolism via
the urea cycle. Recent studies have demonstrated that it is also
expressed in extra-hepatic tissues, including the vascular endothe-
lium. Arginase 2 is a mitochondrial enzyme expressed in various
cell types, including those in the kidneys (1) and the vascula-
ture. In blood vessels, both isoforms likely play a role in the
regulation of l-arginine homeostasis and the production of l-
ornithine for subsequent polyamine and proline synthesis, which
are involved in endothelial and smooth muscle cell proliferation
and collagen deposition (13, 14). Polyamine and proline syn-
thesis are crucial components of physiological and pathological
vascular remodeling, a topic extensively discussed in this issue
by Durante (5). Since both arginase isoforms are expressed in
vascular endothelial cells, they can potentially interfere with the
activity of endothelial nitric oxide synthase (eNOS), by “steal-
ing away” the common substrate l-arginine, required to generate
nitric oxide (NO) and l-citrulline. NO is a crucial mediator
of endothelium-dependent vasorelaxation and restricts vascular
growth and inflammation (14). Therefore, excessive activation of
arginase by pathologic stimuli, including bacterial toxins [e.g.,
LPS and pneumolysin (6)], pro-inflammatory cytokines [e.g., TNF
(15)], reactive oxygen species (ROS) (7, 11), or hyperglycemia (1,
3, 4) can potentially induce severe endothelial dysfunction. This
theory is, however, complicated by observations that even dur-
ing dramatically increased arginase activity, the concentrations of
l-arginine in endothelial cells remain sufficiently high to concep-
tually support eNOS-mediated NO synthesis. As such, this has
led to the suggestion that there is sub-cellular compartmentaliza-
tion of l-arginine into poorly interchangeable intracellular pools,
a topic discussed by Chen et al. in this issue (8). The review
by Yang and Ming (7) gives an overview of the direct role of
arginase in eNOS dysfunction. Indeed, a pathological increase in
vascular arginase activity was shown to significantly contribute
to “eNOS uncoupling,” a phenomenon observed in various vas-
cular pathologies and in aging (16), during which the enzyme
generates detrimental amounts of superoxide instead of the vaso-
protective NO. Decreased NO bioavailability within the vessel wall
induced by competitive utilization of l-arginine by arginase and
“eNOS uncoupling” can be partially circumvented by a recently
discovered alternative pathway of NO generation: the reduction of
nitrate and nitrite, which is the focus of the review by Madigan and
Zuckerbraun (9). Since large vessel endothelial cells are function-
ally and morphologically distinct from microvascular endothelial
cells (17), this review highlights studies on the role of arginase
in both of these cell types. Using a DOCA salt-induced mouse
model in wild type, Arg1+/−Arg2−/− mice, Toque et al. present
original data demonstrating an important role of arginase 1 in
impaired vasorelaxation in the aorta and in hypertension (2). Bagi
et al. present a concise review on the upregulation of arginase 1
expression and its effects on eNOS function in coronary arteries
from diabetic patients (10). Addressing the microvascular com-
partments, Johnson et al. demonstrate that arginase is an essential
mediator of skeletal muscle arteriolar endothelial dysfunction in
diabetes, which may further compromise glucose utilization and
facilitate the development of diabetes and hypertension (3). Acute
pretreatment with l-arginine or with arginase inhibitors signif-
icantly improved endothelial function in skeletal arterioles. Kuo
and Hein review recent data on the role of arginase in the gener-
ation of ROS and the subsequent vasomotor dysfunction of the
coronary microcirculation upon angiotensin 2 receptor activa-
tion (11). Lucas et al. discuss recent findings suggesting a role
for arginase 1 in pneumolysin-induced pulmonary capillary bar-
rier dysfunction (6), which involves impairment of eNOS function
(18). They demonstrate that arginase inhibitors significantly pre-
vent pneumolysin-induced barrier dysfunction, at least in part by
preventing the loss of expression of the adherens junction protein,
VE cadherin (6). Comparing streptozotocin-treated diabetic wild
type with diabetic Arg1+/−Arg2−/− transgenic mice, Patel et al.
demonstrate an important role for arginase in the pathogenesis
of diabetic retinopathy and they extend these findings in vitro in
high glucose-treated bovine retinal endothelial cells. Their results
advance arginase as a potential therapeutic target for preserv-
ing NO bioavailability, limiting oxidative stress, and preventing
early signs of diabetic retinopathy (4). Although acute treatment
with l-arginine was shown to significantly improve endothelial
function in several experimental studies, including those by John-
son et al. in this issue (3), a recent clinical trial in patients with
acute myocardial infarction demonstrated that a 6-month chronic
treatment with l-arginine in addition to standard postinfarct med-
ications did not improve clinical outcomes. Moreover, there was
an increased risk of death in older patients after infarction, which
promoted the early termination of the trial (19). This study clearly
indicates that the long-term treatment with l-arginine is not the
optimal treatment for arginase-mediated endothelial dysfunction
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and stresses the need for alternative strategies to inhibit arginase.
Given the vital role that arginase plays in the detoxification of
ammonia in the urea cycle, this suggests that chronic inhibi-
tion using specific arginase inhibitors should produce severe side
effects. Surprisingly, this does not happen, possibly because the
expression of arginase in the liver is much higher than in the vas-
culature (14). The review by Steppan et al. in this issue discusses
the development of novel ABH-based arginase inhibitors, apart
from the classically used boronic acid derivatives and moreover
addresses potential disadvantages of developing isoform-specific
inhibitors for macrophage function (12). As an alternative to l-
arginine therapies, l-citrulline is a product of NO synthases that
can be recycled to l-arginine. Romero et al. presents data demon-
strating a potent protective action of l-citrulline in streptozotocin-
induced diabetic nephropathy in mice, accompanied by lower
albuminuria and kidney fibrosis (1). l-citrulline also restored the
NO/ROS balance and barrier function in high glucose-treated
monolayers of human glomerular endothelial cells. Intriguingly,
l-citrulline promoted the sustained elevation of arginase 2 expres-
sion/activity in proximal tubule epithelium of kidneys from mice.
This was mediated, at least in part, via a previously unappreci-
ated immunomodulatory ability to significantly increase plasma
levels of the anti-inflammatory cytokine IL-10 (20, 21). Given the
weight of experimental evidence to date, there are little doubts
that arginase plays a significant role in limiting l-arginine utiliza-
tion by eNOS and compromising endothelial function. Currently,
acute l-arginine and arginase inhibitors are effective in improv-
ing endothelial function. However, given the important contri-
butions of arginase to vital metabolic functions, the long-term
consequences of arginase inhibition remain uncertain. Improved
selectivity could perhaps be obtained by elucidating and targeting
the molecular mechanisms that lead to specific upregulation of
arginases in the vascular compartment.
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